nodes	percent_of_prediction	percent_of_DWPC	metapath
Bosutinib—Gefitinib—Lapatinib—breast cancer	0.25	1	CrCrCtD
Bosutinib—ERBB4—Lapatinib—breast cancer	0.0785	0.403	CbGbCtD
Bosutinib—EPHB4—breast cancer	0.0493	0.157	CbGaD
Bosutinib—BMPR2—breast cancer	0.0493	0.157	CbGaD
Bosutinib—CDK2—breast cancer	0.0451	0.144	CbGaD
Bosutinib—BTK—Mitoxantrone—breast cancer	0.0383	0.197	CbGbCtD
Bosutinib—EGFR—Lapatinib—breast cancer	0.0358	0.184	CbGbCtD
Bosutinib—ERBB4—breast cancer	0.029	0.0927	CbGaD
Bosutinib—CHEK2—breast cancer	0.0254	0.081	CbGaD
Bosutinib—ERBB3—breast cancer	0.0226	0.0722	CbGaD
Bosutinib—ALK—breast cancer	0.0226	0.0722	CbGaD
Bosutinib—CSF1R—breast cancer	0.0215	0.0684	CbGaD
Bosutinib—ABL1—breast cancer	0.0167	0.0532	CbGaD
Bosutinib—SRC—breast cancer	0.0151	0.0482	CbGaD
Bosutinib—EGFR—breast cancer	0.0101	0.0324	CbGaD
Bosutinib—EGFR—Docetaxel—breast cancer	0.0101	0.0518	CbGbCtD
Bosutinib—CYP3A4—breast cancer	0.00371	0.0118	CbGaD
Bosutinib—ABCB1—breast cancer	0.00309	0.00984	CbGaD
Bosutinib—ABCB1—Toremifene—breast cancer	0.00292	0.015	CbGbCtD
Bosutinib—CYP3A4—Exemestane—breast cancer	0.00253	0.013	CbGbCtD
Bosutinib—CYP3A4—Letrozole—breast cancer	0.00215	0.011	CbGbCtD
Bosutinib—ABCB1—Lapatinib—breast cancer	0.00213	0.0109	CbGbCtD
Bosutinib—CYP3A4—Anastrozole—breast cancer	0.00192	0.00983	CbGbCtD
Bosutinib—CYP3A4—Toremifene—breast cancer	0.00175	0.00899	CbGbCtD
Bosutinib—CYP3A4—Fulvestrant—breast cancer	0.00163	0.00835	CbGbCtD
Bosutinib—CYP3A4—Thiotepa—breast cancer	0.00145	0.00745	CbGbCtD
Bosutinib—CYP3A4—Ixabepilone—breast cancer	0.00133	0.00681	CbGbCtD
Bosutinib—CYP3A4—Lapatinib—breast cancer	0.00128	0.00656	CbGbCtD
Bosutinib—ABCB1—Vinorelbine—breast cancer	0.00118	0.00607	CbGbCtD
Bosutinib—ABCB1—Tamoxifen—breast cancer	0.00107	0.00548	CbGbCtD
Bosutinib—ABCB1—Mitoxantrone—breast cancer	0.00104	0.00534	CbGbCtD
Bosutinib—CYP3A4—Raloxifene—breast cancer	0.000969	0.00497	CbGbCtD
Bosutinib—ABCB1—Gemcitabine—breast cancer	0.00092	0.00472	CbGbCtD
Bosutinib—ABCB1—Paclitaxel—breast cancer	0.000831	0.00426	CbGbCtD
Bosutinib—ABCB1—Irinotecan—breast cancer	0.00082	0.00421	CbGbCtD
Bosutinib—ABCB1—Vinblastine—breast cancer	0.000729	0.00374	CbGbCtD
Bosutinib—CYP3A4—Vinorelbine—breast cancer	0.000709	0.00364	CbGbCtD
Bosutinib—CYP3A4—Tamoxifen—breast cancer	0.00064	0.00328	CbGbCtD
Bosutinib—CYP3A4—Mitoxantrone—breast cancer	0.000624	0.0032	CbGbCtD
Bosutinib—ABCB1—Docetaxel—breast cancer	0.000601	0.00308	CbGbCtD
Bosutinib—CYP3A4—Paclitaxel—breast cancer	0.000498	0.00256	CbGbCtD
Bosutinib—CYP3A4—Irinotecan—breast cancer	0.000491	0.00252	CbGbCtD
Bosutinib—ABCB1—Doxorubicin—breast cancer	0.000448	0.0023	CbGbCtD
Bosutinib—CYP3A4—Vinblastine—breast cancer	0.000437	0.00224	CbGbCtD
Bosutinib—ABCB1—Methotrexate—breast cancer	0.000434	0.00223	CbGbCtD
Bosutinib—CYP3A4—Docetaxel—breast cancer	0.00036	0.00185	CbGbCtD
Bosutinib—CYP3A4—Doxorubicin—breast cancer	0.000268	0.00138	CbGbCtD
Bosutinib—Gefitinib—CHEK2—breast cancer	0.000262	0.12	CrCbGaD
Bosutinib—Vandetanib—ERBB3—breast cancer	0.000245	0.113	CrCbGaD
Bosutinib—Gefitinib—ERBB3—breast cancer	0.000233	0.107	CrCbGaD
Bosutinib—Vandetanib—ABL1—breast cancer	0.000181	0.0832	CrCbGaD
Bosutinib—WEE1—Paclitaxel—Docetaxel—breast cancer	0.000168	0.0977	CbGdCrCtD
Bosutinib—Vandetanib—SRC—breast cancer	0.000164	0.0753	CrCbGaD
Bosutinib—Vandetanib—KDR—breast cancer	0.000154	0.0707	CrCbGaD
Bosutinib—Vandetanib—ABCC1—breast cancer	0.000152	0.0701	CrCbGaD
Bosutinib—CDK2—Paclitaxel—Docetaxel—breast cancer	0.000137	0.0797	CbGdCrCtD
Bosutinib—Vandetanib—VEGFA—breast cancer	0.00013	0.06	CrCbGaD
Bosutinib—WEE1—Daunorubicin—Idarubicin—breast cancer	0.000122	0.0713	CbGdCrCtD
Bosutinib—Vandetanib—EGFR—breast cancer	0.00011	0.0506	CrCbGaD
Bosutinib—Gefitinib—EGFR—breast cancer	0.000105	0.0481	CrCbGaD
Bosutinib—CHEK2—Docetaxel—Paclitaxel—breast cancer	8.39e-05	0.049	CbGdCrCtD
Bosutinib—Vandetanib—ABCG2—breast cancer	8.04e-05	0.037	CrCbGaD
Bosutinib—Gefitinib—ABCG2—breast cancer	7.64e-05	0.0351	CrCbGaD
Bosutinib—CDK2—Vinblastine—Vinorelbine—breast cancer	7.55e-05	0.0441	CbGdCrCtD
Bosutinib—MAP4K4—Testosterone Propionate—Fluoxymesterone—breast cancer	6.01e-05	0.0351	CbGdCrCtD
Bosutinib—Gefitinib—CYP1A1—breast cancer	5.98e-05	0.0275	CrCbGaD
Bosutinib—ABL1—Topotecan—Irinotecan—breast cancer	5.69e-05	0.0332	CbGdCrCtD
Bosutinib—WEE1—Daunorubicin—Epirubicin—breast cancer	5.61e-05	0.0327	CbGdCrCtD
Bosutinib—IRAK4—bone marrow—breast cancer	5.57e-05	0.000932	CbGeAlD
Bosutinib—FYN—uterus—breast cancer	5.56e-05	0.000931	CbGeAlD
Bosutinib—SRC—skin of body—breast cancer	5.56e-05	0.00093	CbGeAlD
Bosutinib—EPHB4—adipose tissue—breast cancer	5.55e-05	0.000929	CbGeAlD
Bosutinib—MAP2K1—endocrine gland—breast cancer	5.54e-05	0.000928	CbGeAlD
Bosutinib—STK35—endocrine gland—breast cancer	5.54e-05	0.000928	CbGeAlD
Bosutinib—PTK2B—female gonad—breast cancer	5.54e-05	0.000928	CbGeAlD
Bosutinib—MAP3K7—adrenal gland—breast cancer	5.54e-05	0.000927	CbGeAlD
Bosutinib—CHEK2—lymph node—breast cancer	5.53e-05	0.000925	CbGeAlD
Bosutinib—CSK—endocrine gland—breast cancer	5.51e-05	0.000922	CbGeAlD
Bosutinib—IRAK1—female reproductive system—breast cancer	5.5e-05	0.00092	CbGeAlD
Bosutinib—DMPK—lymph node—breast cancer	5.48e-05	0.000918	CbGeAlD
Bosutinib—WEE1—lymph node—breast cancer	5.48e-05	0.000918	CbGeAlD
Bosutinib—PTK2—adrenal gland—breast cancer	5.47e-05	0.000916	CbGeAlD
Bosutinib—TBK1—adrenal gland—breast cancer	5.47e-05	0.000916	CbGeAlD
Bosutinib—CSNK1A1—endocrine gland—breast cancer	5.47e-05	0.000916	CbGeAlD
Bosutinib—EPHA2—pituitary gland—breast cancer	5.47e-05	0.000916	CbGeAlD
Bosutinib—FYN—pituitary gland—breast cancer	5.46e-05	0.000914	CbGeAlD
Bosutinib—CSNK1E—female gonad—breast cancer	5.45e-05	0.000913	CbGeAlD
Bosutinib—EPHA2—adipose tissue—breast cancer	5.45e-05	0.000912	CbGeAlD
Bosutinib—YES1—endometrium—breast cancer	5.45e-05	0.000912	CbGeAlD
Bosutinib—MAP2K2—bone marrow—breast cancer	5.45e-05	0.000911	CbGeAlD
Bosutinib—ULK3—bone marrow—breast cancer	5.45e-05	0.000911	CbGeAlD
Bosutinib—FYN—adipose tissue—breast cancer	5.44e-05	0.00091	CbGeAlD
Bosutinib—CLK1—endocrine gland—breast cancer	5.44e-05	0.00091	CbGeAlD
Bosutinib—HCK—endocrine gland—breast cancer	5.44e-05	0.00091	CbGeAlD
Bosutinib—MAP4K5—uterus—breast cancer	5.43e-05	0.000909	CbGeAlD
Bosutinib—MAP3K2—bone marrow—breast cancer	5.41e-05	0.000905	CbGeAlD
Bosutinib—RPS6KB1—female reproductive system—breast cancer	5.39e-05	0.000903	CbGeAlD
Bosutinib—TAOK3—endometrium—breast cancer	5.38e-05	0.0009	CbGeAlD
Bosutinib—SIK1—female gonad—breast cancer	5.37e-05	0.000898	CbGeAlD
Bosutinib—IRAK4—female gonad—breast cancer	5.37e-05	0.000898	CbGeAlD
Bosutinib—IRAK1—adrenal gland—breast cancer	5.37e-05	0.000898	CbGeAlD
Bosutinib—FGR—female reproductive system—breast cancer	5.36e-05	0.000898	CbGeAlD
Bosutinib—MAP3K7—bone marrow—breast cancer	5.36e-05	0.000896	CbGeAlD
Bosutinib—AXL—female reproductive system—breast cancer	5.34e-05	0.000894	CbGeAlD
Bosutinib—CAMK2G—endocrine gland—breast cancer	5.34e-05	0.000893	CbGeAlD
Bosutinib—BMP2K—endocrine gland—breast cancer	5.34e-05	0.000893	CbGeAlD
Bosutinib—CHEK2—Vindesine—Vinorelbine—breast cancer	5.34e-05	0.0311	CbGdCrCtD
Bosutinib—MAP3K3—pituitary gland—breast cancer	5.34e-05	0.000893	CbGeAlD
Bosutinib—MAP4K5—pituitary gland—breast cancer	5.34e-05	0.000893	CbGeAlD
Bosutinib—MAP4K5—adipose tissue—breast cancer	5.31e-05	0.00089	CbGeAlD
Bosutinib—MAP3K3—adipose tissue—breast cancer	5.31e-05	0.00089	CbGeAlD
Bosutinib—EPHA4—female gonad—breast cancer	5.31e-05	0.000889	CbGeAlD
Bosutinib—TBK1—bone marrow—breast cancer	5.29e-05	0.000886	CbGeAlD
Bosutinib—LRRK2—endocrine gland—breast cancer	5.29e-05	0.000885	CbGeAlD
Bosutinib—RPS6KB1—adrenal gland—breast cancer	5.26e-05	0.000881	CbGeAlD
Bosutinib—ERBB3—female gonad—breast cancer	5.26e-05	0.000881	CbGeAlD
Bosutinib—MAP2K2—female gonad—breast cancer	5.25e-05	0.000878	CbGeAlD
Bosutinib—ULK3—female gonad—breast cancer	5.25e-05	0.000878	CbGeAlD
Bosutinib—STK25—lymph node—breast cancer	5.24e-05	0.000876	CbGeAlD
Bosutinib—LCK—adrenal gland—breast cancer	5.23e-05	0.000876	CbGeAlD
Bosutinib—FGR—adrenal gland—breast cancer	5.23e-05	0.000876	CbGeAlD
Bosutinib—AXL—adrenal gland—breast cancer	5.21e-05	0.000872	CbGeAlD
Bosutinib—MAP3K2—female gonad—breast cancer	5.21e-05	0.000872	CbGeAlD
Bosutinib—EPHA3—lymph node—breast cancer	5.2e-05	0.00087	CbGeAlD
Bosutinib—WEE1—Daunorubicin—Doxorubicin—breast cancer	5.19e-05	0.0303	CbGdCrCtD
Bosutinib—IRAK1—bone marrow—breast cancer	5.19e-05	0.000869	CbGeAlD
Bosutinib—MAP3K7—female gonad—breast cancer	5.16e-05	0.000864	CbGeAlD
Bosutinib—PTK2B—endocrine gland—breast cancer	5.15e-05	0.000863	CbGeAlD
Bosutinib—EPHB4—female reproductive system—breast cancer	5.1e-05	0.000854	CbGeAlD
Bosutinib—TBK1—female gonad—breast cancer	5.1e-05	0.000854	CbGeAlD
Bosutinib—PTK2—female gonad—breast cancer	5.1e-05	0.000854	CbGeAlD
Bosutinib—RPS6KB1—bone marrow—breast cancer	5.09e-05	0.000853	CbGeAlD
Bosutinib—PLK2—lymph node—breast cancer	5.09e-05	0.000852	CbGeAlD
Bosutinib—ABL1—embryo—breast cancer	5.08e-05	0.00085	CbGeAlD
Bosutinib—CSNK1E—endocrine gland—breast cancer	5.07e-05	0.000849	CbGeAlD
Bosutinib—FGR—bone marrow—breast cancer	5.06e-05	0.000847	CbGeAlD
Bosutinib—LCK—bone marrow—breast cancer	5.06e-05	0.000847	CbGeAlD
Bosutinib—SIK3—lymph node—breast cancer	5.06e-05	0.000846	CbGeAlD
Bosutinib—YES1—uterus—breast cancer	5.02e-05	0.00084	CbGeAlD
Bosutinib—SLK—adrenal gland—breast cancer	5.02e-05	0.00084	CbGeAlD
Bosutinib—EPHA2—female reproductive system—breast cancer	5.01e-05	0.000838	CbGeAlD
Bosutinib—IRAK1—female gonad—breast cancer	5e-05	0.000837	CbGeAlD
Bosutinib—FYN—female reproductive system—breast cancer	5e-05	0.000837	CbGeAlD
Bosutinib—SIK1—endocrine gland—breast cancer	4.99e-05	0.000836	CbGeAlD
Bosutinib—CSF1R—skin of body—breast cancer	4.99e-05	0.000835	CbGeAlD
Bosutinib—EPHB4—adrenal gland—breast cancer	4.98e-05	0.000834	CbGeAlD
Bosutinib—STK10—uterus—breast cancer	4.97e-05	0.000832	CbGeAlD
Bosutinib—TAOK3—uterus—breast cancer	4.95e-05	0.000829	CbGeAlD
Bosutinib—EPHA4—endocrine gland—breast cancer	4.94e-05	0.000827	CbGeAlD
Bosutinib—YES1—pituitary gland—breast cancer	4.93e-05	0.000825	CbGeAlD
Bosutinib—RPS6KB1—female gonad—breast cancer	4.91e-05	0.000822	CbGeAlD
Bosutinib—YES1—adipose tissue—breast cancer	4.91e-05	0.000821	CbGeAlD
Bosutinib—ERBB3—endocrine gland—breast cancer	4.89e-05	0.000819	CbGeAlD
Bosutinib—EPHA2—adrenal gland—breast cancer	4.89e-05	0.000818	CbGeAlD
Bosutinib—MAP3K3—female reproductive system—breast cancer	4.88e-05	0.000818	CbGeAlD
Bosutinib—MAP4K5—female reproductive system—breast cancer	4.88e-05	0.000818	CbGeAlD
Bosutinib—MAP2K2—endocrine gland—breast cancer	4.88e-05	0.000817	CbGeAlD
Bosutinib—ULK3—endocrine gland—breast cancer	4.88e-05	0.000817	CbGeAlD
Bosutinib—FGR—female gonad—breast cancer	4.88e-05	0.000817	CbGeAlD
Bosutinib—LCK—female gonad—breast cancer	4.88e-05	0.000817	CbGeAlD
Bosutinib—FYN—adrenal gland—breast cancer	4.88e-05	0.000816	CbGeAlD
Bosutinib—STK4—lymph node—breast cancer	4.87e-05	0.000815	CbGeAlD
Bosutinib—TAOK3—pituitary gland—breast cancer	4.86e-05	0.000814	CbGeAlD
Bosutinib—STK10—adipose tissue—breast cancer	4.86e-05	0.000814	CbGeAlD
Bosutinib—AXL—female gonad—breast cancer	4.86e-05	0.000813	CbGeAlD
Bosutinib—SLK—bone marrow—breast cancer	4.85e-05	0.000812	CbGeAlD
Bosutinib—MAP3K2—endocrine gland—breast cancer	4.85e-05	0.000811	CbGeAlD
Bosutinib—TAOK3—adipose tissue—breast cancer	4.84e-05	0.000811	CbGeAlD
Bosutinib—MAP2K5—endometrium—breast cancer	4.82e-05	0.000807	CbGeAlD
Bosutinib—EPHB4—bone marrow—breast cancer	4.82e-05	0.000807	CbGeAlD
Bosutinib—CAMK1D—lymph node—breast cancer	4.81e-05	0.000805	CbGeAlD
Bosutinib—MAP3K3—adrenal gland—breast cancer	4.77e-05	0.000798	CbGeAlD
Bosutinib—MAP4K5—adrenal gland—breast cancer	4.77e-05	0.000798	CbGeAlD
Bosutinib—STK24—lymph node—breast cancer	4.75e-05	0.000796	CbGeAlD
Bosutinib—TBK1—endocrine gland—breast cancer	4.75e-05	0.000794	CbGeAlD
Bosutinib—PTK2—endocrine gland—breast cancer	4.75e-05	0.000794	CbGeAlD
Bosutinib—SRC—adipose tissue—breast cancer	4.72e-05	0.00079	CbGeAlD
Bosutinib—FYN—bone marrow—breast cancer	4.72e-05	0.00079	CbGeAlD
Bosutinib—CSF1R—endometrium—breast cancer	4.7e-05	0.000787	CbGeAlD
Bosutinib—SLK—female gonad—breast cancer	4.68e-05	0.000783	CbGeAlD
Bosutinib—PDGFRB—epithelium—breast cancer	4.65e-05	0.000779	CbGeAlD
Bosutinib—EPHB4—female gonad—breast cancer	4.64e-05	0.000777	CbGeAlD
Bosutinib—MAP4K5—bone marrow—breast cancer	4.61e-05	0.000772	CbGeAlD
Bosutinib—MAP3K3—bone marrow—breast cancer	4.61e-05	0.000772	CbGeAlD
Bosutinib—ALK—lymph node—breast cancer	4.6e-05	0.00077	CbGeAlD
Bosutinib—FER—lymph node—breast cancer	4.6e-05	0.00077	CbGeAlD
Bosutinib—RPS6KB1—endocrine gland—breast cancer	4.57e-05	0.000764	CbGeAlD
Bosutinib—EPHA2—female gonad—breast cancer	4.56e-05	0.000763	CbGeAlD
Bosutinib—FYN—female gonad—breast cancer	4.55e-05	0.000761	CbGeAlD
Bosutinib—FGR—endocrine gland—breast cancer	4.54e-05	0.00076	CbGeAlD
Bosutinib—AXL—endocrine gland—breast cancer	4.52e-05	0.000756	CbGeAlD
Bosutinib—YES1—female reproductive system—breast cancer	4.51e-05	0.000755	CbGeAlD
Bosutinib—MAP4K1—lymph node—breast cancer	4.51e-05	0.000754	CbGeAlD
Bosutinib—BTK—lymph node—breast cancer	4.48e-05	0.000751	CbGeAlD
Bosutinib—STK10—female reproductive system—breast cancer	4.47e-05	0.000748	CbGeAlD
Bosutinib—TAOK3—female reproductive system—breast cancer	4.45e-05	0.000745	CbGeAlD
Bosutinib—Gefitinib—CYP2D6—breast cancer	4.45e-05	0.0205	CrCbGaD
Bosutinib—MAP3K3—female gonad—breast cancer	4.44e-05	0.000744	CbGeAlD
Bosutinib—MAP4K5—female gonad—breast cancer	4.44e-05	0.000744	CbGeAlD
Bosutinib—PDGFRB—skin of body—breast cancer	4.42e-05	0.000741	CbGeAlD
Bosutinib—TNK2—lymph node—breast cancer	4.42e-05	0.00074	CbGeAlD
Bosutinib—YES1—adrenal gland—breast cancer	4.4e-05	0.000737	CbGeAlD
Bosutinib—STK10—adrenal gland—breast cancer	4.36e-05	0.00073	CbGeAlD
Bosutinib—MAP2K5—pituitary gland—breast cancer	4.36e-05	0.00073	CbGeAlD
Bosutinib—MAP4K2—lymph node—breast cancer	4.36e-05	0.00073	CbGeAlD
Bosutinib—TAOK3—adrenal gland—breast cancer	4.35e-05	0.000727	CbGeAlD
Bosutinib—MAP2K5—adipose tissue—breast cancer	4.34e-05	0.000727	CbGeAlD
Bosutinib—SRC—female reproductive system—breast cancer	4.34e-05	0.000726	CbGeAlD
Bosutinib—CAMK2G—Azacitidine—Gemcitabine—breast cancer	4.34e-05	0.0253	CbGdCrCtD
Bosutinib—CSF1R—uterus—breast cancer	4.33e-05	0.000725	CbGeAlD
Bosutinib—EPHB4—endocrine gland—breast cancer	4.32e-05	0.000723	CbGeAlD
Bosutinib—STK3—lymph node—breast cancer	4.3e-05	0.00072	CbGeAlD
Bosutinib—CHEK2—Vindesine—Vinblastine—breast cancer	4.27e-05	0.0249	CbGdCrCtD
Bosutinib—YES1—bone marrow—breast cancer	4.26e-05	0.000713	CbGeAlD
Bosutinib—CSF1R—pituitary gland—breast cancer	4.26e-05	0.000712	CbGeAlD
Bosutinib—CSF1R—adipose tissue—breast cancer	4.24e-05	0.000709	CbGeAlD
Bosutinib—EPHA2—endocrine gland—breast cancer	4.24e-05	0.000709	CbGeAlD
Bosutinib—SRC—adrenal gland—breast cancer	4.23e-05	0.000709	CbGeAlD
Bosutinib—FYN—endocrine gland—breast cancer	4.23e-05	0.000708	CbGeAlD
Bosutinib—STK10—bone marrow—breast cancer	4.22e-05	0.000706	CbGeAlD
Bosutinib—TAOK3—bone marrow—breast cancer	4.2e-05	0.000704	CbGeAlD
Bosutinib—CHEK2—Paclitaxel—Docetaxel—breast cancer	4.19e-05	0.0244	CbGdCrCtD
Bosutinib—CSK—Daunorubicin—Idarubicin—breast cancer	4.17e-05	0.0244	CbGdCrCtD
Bosutinib—CSK—Doxorubicin—Idarubicin—breast cancer	4.17e-05	0.0244	CbGdCrCtD
Bosutinib—CSK—Epirubicin—Idarubicin—breast cancer	4.17e-05	0.0244	CbGdCrCtD
Bosutinib—PDGFRB—endometrium—breast cancer	4.17e-05	0.000698	CbGeAlD
Bosutinib—MAP4K5—endocrine gland—breast cancer	4.13e-05	0.000692	CbGeAlD
Bosutinib—MAP3K3—endocrine gland—breast cancer	4.13e-05	0.000692	CbGeAlD
Bosutinib—BMPR2—lymph node—breast cancer	4.12e-05	0.00069	CbGeAlD
Bosutinib—YES1—female gonad—breast cancer	4.1e-05	0.000687	CbGeAlD
Bosutinib—STK36—lymph node—breast cancer	4.09e-05	0.000685	CbGeAlD
Bosutinib—EPHB3—lymph node—breast cancer	4.09e-05	0.000685	CbGeAlD
Bosutinib—STK10—female gonad—breast cancer	4.07e-05	0.000681	CbGeAlD
Bosutinib—TAOK3—female gonad—breast cancer	4.05e-05	0.000678	CbGeAlD
Bosutinib—MERTK—lymph node—breast cancer	4.04e-05	0.000677	CbGeAlD
Bosutinib—Vandetanib—CYP3A4—breast cancer	4.02e-05	0.0185	CrCbGaD
Bosutinib—MAP2K5—female reproductive system—breast cancer	3.99e-05	0.000668	CbGeAlD
Bosutinib—MAP4K4—lymph node—breast cancer	3.97e-05	0.000664	CbGeAlD
Bosutinib—SRC—female gonad—breast cancer	3.95e-05	0.000661	CbGeAlD
Bosutinib—ABL1—skin of body—breast cancer	3.94e-05	0.00066	CbGeAlD
Bosutinib—BCR—lymph node—breast cancer	3.94e-05	0.000659	CbGeAlD
Bosutinib—NUAK2—lymph node—breast cancer	3.94e-05	0.000659	CbGeAlD
Bosutinib—MAP3K12—lymph node—breast cancer	3.91e-05	0.000655	CbGeAlD
Bosutinib—CSF1R—female reproductive system—breast cancer	3.9e-05	0.000652	CbGeAlD
Bosutinib—MAP2K5—adrenal gland—breast cancer	3.9e-05	0.000652	CbGeAlD
Bosutinib—PDGFRB—uterus—breast cancer	3.84e-05	0.000643	CbGeAlD
Bosutinib—STK35—lymph node—breast cancer	3.83e-05	0.000641	CbGeAlD
Bosutinib—MAP2K1—lymph node—breast cancer	3.83e-05	0.000641	CbGeAlD
Bosutinib—Gefitinib—CYP3A4—breast cancer	3.82e-05	0.0176	CrCbGaD
Bosutinib—YES1—endocrine gland—breast cancer	3.82e-05	0.000639	CbGeAlD
Bosutinib—CSK—lymph node—breast cancer	3.81e-05	0.000637	CbGeAlD
Bosutinib—CSF1R—adrenal gland—breast cancer	3.8e-05	0.000636	CbGeAlD
Bosutinib—STK10—endocrine gland—breast cancer	3.78e-05	0.000633	CbGeAlD
Bosutinib—CSNK1A1—lymph node—breast cancer	3.78e-05	0.000633	CbGeAlD
Bosutinib—PDGFRB—pituitary gland—breast cancer	3.77e-05	0.000632	CbGeAlD
Bosutinib—TAOK3—endocrine gland—breast cancer	3.77e-05	0.000631	CbGeAlD
Bosutinib—PDGFRB—adipose tissue—breast cancer	3.76e-05	0.000629	CbGeAlD
Bosutinib—HCK—lymph node—breast cancer	3.76e-05	0.000629	CbGeAlD
Bosutinib—CLK1—lymph node—breast cancer	3.76e-05	0.000629	CbGeAlD
Bosutinib—ABL2—lymph node—breast cancer	3.73e-05	0.000625	CbGeAlD
Bosutinib—ABL1—endometrium—breast cancer	3.72e-05	0.000622	CbGeAlD
Bosutinib—CAMK2G—lymph node—breast cancer	3.69e-05	0.000617	CbGeAlD
Bosutinib—BMP2K—lymph node—breast cancer	3.69e-05	0.000617	CbGeAlD
Bosutinib—CSF1R—bone marrow—breast cancer	3.68e-05	0.000616	CbGeAlD
Bosutinib—SRC—endocrine gland—breast cancer	3.67e-05	0.000615	CbGeAlD
Bosutinib—LRRK2—lymph node—breast cancer	3.66e-05	0.000612	CbGeAlD
Bosutinib—EGFR—lymph node—breast cancer	3.65e-05	0.00061	CbGeAlD
Bosutinib—MAP2K5—female gonad—breast cancer	3.63e-05	0.000608	CbGeAlD
Bosutinib—PTK2B—lymph node—breast cancer	3.56e-05	0.000596	CbGeAlD
Bosutinib—CSF1R—female gonad—breast cancer	3.54e-05	0.000593	CbGeAlD
Bosutinib—Vandetanib—ALB—breast cancer	3.51e-05	0.0161	CrCbGaD
Bosutinib—CSNK1E—lymph node—breast cancer	3.51e-05	0.000587	CbGeAlD
Bosutinib—PDGFRB—female reproductive system—breast cancer	3.46e-05	0.000578	CbGeAlD
Bosutinib—SIK1—lymph node—breast cancer	3.45e-05	0.000578	CbGeAlD
Bosutinib—IRAK4—lymph node—breast cancer	3.45e-05	0.000578	CbGeAlD
Bosutinib—ERBB3—Vinblastine—Vinorelbine—breast cancer	3.43e-05	0.02	CbGdCrCtD
Bosutinib—ABL1—uterus—breast cancer	3.43e-05	0.000573	CbGeAlD
Bosutinib—EPHA4—lymph node—breast cancer	3.42e-05	0.000572	CbGeAlD
Bosutinib—ERBB3—lymph node—breast cancer	3.38e-05	0.000566	CbGeAlD
Bosutinib—MAP2K5—endocrine gland—breast cancer	3.38e-05	0.000565	CbGeAlD
Bosutinib—ULK3—lymph node—breast cancer	3.37e-05	0.000565	CbGeAlD
Bosutinib—MAP2K2—lymph node—breast cancer	3.37e-05	0.000565	CbGeAlD
Bosutinib—PDGFRB—adrenal gland—breast cancer	3.37e-05	0.000564	CbGeAlD
Bosutinib—ABL1—pituitary gland—breast cancer	3.36e-05	0.000563	CbGeAlD
Bosutinib—ABL1—adipose tissue—breast cancer	3.35e-05	0.000561	CbGeAlD
Bosutinib—MAP3K2—lymph node—breast cancer	3.35e-05	0.000561	CbGeAlD
Bosutinib—Gefitinib—ALB—breast cancer	3.33e-05	0.0153	CrCbGaD
Bosutinib—MAP3K7—lymph node—breast cancer	3.32e-05	0.000555	CbGeAlD
Bosutinib—CSF1R—endocrine gland—breast cancer	3.3e-05	0.000552	CbGeAlD
Bosutinib—TBK1—lymph node—breast cancer	3.28e-05	0.000549	CbGeAlD
Bosutinib—PTK2—lymph node—breast cancer	3.28e-05	0.000549	CbGeAlD
Bosutinib—PDGFRB—bone marrow—breast cancer	3.26e-05	0.000546	CbGeAlD
Bosutinib—IRAK1—lymph node—breast cancer	3.22e-05	0.000538	CbGeAlD
Bosutinib—Gefitinib—ABCB1—breast cancer	3.18e-05	0.0146	CrCbGaD
Bosutinib—RPS6KB1—lymph node—breast cancer	3.16e-05	0.000528	CbGeAlD
Bosutinib—PDGFRB—female gonad—breast cancer	3.14e-05	0.000526	CbGeAlD
Bosutinib—FGR—lymph node—breast cancer	3.14e-05	0.000525	CbGeAlD
Bosutinib—LCK—lymph node—breast cancer	3.14e-05	0.000525	CbGeAlD
Bosutinib—AXL—lymph node—breast cancer	3.12e-05	0.000523	CbGeAlD
Bosutinib—ABL1—female reproductive system—breast cancer	3.08e-05	0.000515	CbGeAlD
Bosutinib—CHEK2—Epirubicin—Idarubicin—breast cancer	3.05e-05	0.0178	CbGdCrCtD
Bosutinib—CHEK2—Doxorubicin—Idarubicin—breast cancer	3.05e-05	0.0178	CbGdCrCtD
Bosutinib—SLK—lymph node—breast cancer	3.01e-05	0.000503	CbGeAlD
Bosutinib—ABL1—adrenal gland—breast cancer	3.01e-05	0.000503	CbGeAlD
Bosutinib—EPHB4—lymph node—breast cancer	2.99e-05	0.0005	CbGeAlD
Bosutinib—EPHA2—lymph node—breast cancer	2.93e-05	0.00049	CbGeAlD
Bosutinib—PDGFRB—endocrine gland—breast cancer	2.92e-05	0.000489	CbGeAlD
Bosutinib—FYN—lymph node—breast cancer	2.92e-05	0.000489	CbGeAlD
Bosutinib—ABL1—Daunorubicin—Idarubicin—breast cancer	2.91e-05	0.017	CbGdCrCtD
Bosutinib—ABL1—Doxorubicin—Idarubicin—breast cancer	2.91e-05	0.017	CbGdCrCtD
Bosutinib—ABL1—Epirubicin—Idarubicin—breast cancer	2.91e-05	0.017	CbGdCrCtD
Bosutinib—ABL1—bone marrow—breast cancer	2.91e-05	0.000487	CbGeAlD
Bosutinib—CHEK2—Vincristine—Vinorelbine—breast cancer	2.88e-05	0.0168	CbGdCrCtD
Bosutinib—PKMYT1—Danazol—Fluoxymesterone—breast cancer	2.87e-05	0.0168	CbGdCrCtD
Bosutinib—MAP4K5—lymph node—breast cancer	2.86e-05	0.000478	CbGeAlD
Bosutinib—MAP3K3—lymph node—breast cancer	2.86e-05	0.000478	CbGeAlD
Bosutinib—ABL1—female gonad—breast cancer	2.8e-05	0.000469	CbGeAlD
Bosutinib—CSNK1E—Danazol—Fluoxymesterone—breast cancer	2.74e-05	0.016	CbGdCrCtD
Bosutinib—CHEK2—Vinorelbine—Vinblastine—breast cancer	2.69e-05	0.0157	CbGdCrCtD
Bosutinib—YES1—lymph node—breast cancer	2.64e-05	0.000442	CbGeAlD
Bosutinib—STK10—lymph node—breast cancer	2.61e-05	0.000438	CbGeAlD
Bosutinib—ABL1—endocrine gland—breast cancer	2.61e-05	0.000436	CbGeAlD
Bosutinib—TAOK3—lymph node—breast cancer	2.6e-05	0.000436	CbGeAlD
Bosutinib—SRC—lymph node—breast cancer	2.54e-05	0.000425	CbGeAlD
Bosutinib—MAP2K5—lymph node—breast cancer	2.34e-05	0.000391	CbGeAlD
Bosutinib—CHEK2—Vinblastine—Vinorelbine—breast cancer	2.32e-05	0.0135	CbGdCrCtD
Bosutinib—CHEK2—Vincristine—Vinblastine—breast cancer	2.3e-05	0.0134	CbGdCrCtD
Bosutinib—CSF1R—lymph node—breast cancer	2.28e-05	0.000381	CbGeAlD
Bosutinib—PDGFRB—lymph node—breast cancer	2.02e-05	0.000338	CbGeAlD
Bosutinib—CSK—Doxorubicin—Epirubicin—breast cancer	1.92e-05	0.0112	CbGdCrCtD
Bosutinib—CSK—Daunorubicin—Epirubicin—breast cancer	1.92e-05	0.0112	CbGdCrCtD
Bosutinib—Chest pain—Capecitabine—breast cancer	1.91e-05	0.000259	CcSEcCtD
Bosutinib—Arthralgia—Capecitabine—breast cancer	1.91e-05	0.000259	CcSEcCtD
Bosutinib—Myalgia—Capecitabine—breast cancer	1.91e-05	0.000259	CcSEcCtD
Bosutinib—Pain—Paclitaxel—breast cancer	1.9e-05	0.000259	CcSEcCtD
Bosutinib—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—breast cancer	1.89e-05	0.000257	CcSEcCtD
Bosutinib—Urinary tract disorder—Methotrexate—breast cancer	1.89e-05	0.000257	CcSEcCtD
Bosutinib—Hepatobiliary disease—Epirubicin—breast cancer	1.89e-05	0.000257	CcSEcCtD
Bosutinib—Anaphylactic shock—Docetaxel—breast cancer	1.89e-05	0.000257	CcSEcCtD
Bosutinib—Oedema—Docetaxel—breast cancer	1.89e-05	0.000257	CcSEcCtD
Bosutinib—Discomfort—Capecitabine—breast cancer	1.88e-05	0.000256	CcSEcCtD
Bosutinib—Pruritus—Gemcitabine—breast cancer	1.88e-05	0.000256	CcSEcCtD
Bosutinib—Nausea—Thiotepa—breast cancer	1.88e-05	0.000255	CcSEcCtD
Bosutinib—Urethral disorder—Methotrexate—breast cancer	1.88e-05	0.000255	CcSEcCtD
Bosutinib—Infection—Docetaxel—breast cancer	1.88e-05	0.000255	CcSEcCtD
Bosutinib—Diarrhoea—Irinotecan—breast cancer	1.87e-05	0.000254	CcSEcCtD
Bosutinib—Diarrhoea—Mitoxantrone—breast cancer	1.87e-05	0.000254	CcSEcCtD
Bosutinib—Agranulocytosis—Epirubicin—breast cancer	1.86e-05	0.000253	CcSEcCtD
Bosutinib—Pneumonia—Doxorubicin—breast cancer	1.86e-05	0.000253	CcSEcCtD
Bosutinib—Nervous system disorder—Docetaxel—breast cancer	1.85e-05	0.000252	CcSEcCtD
Bosutinib—Pruritus—Fluorouracil—breast cancer	1.85e-05	0.000252	CcSEcCtD
Bosutinib—Thrombocytopenia—Docetaxel—breast cancer	1.85e-05	0.000251	CcSEcCtD
Bosutinib—Infestation—Doxorubicin—breast cancer	1.85e-05	0.000251	CcSEcCtD
Bosutinib—Infestation NOS—Doxorubicin—breast cancer	1.85e-05	0.000251	CcSEcCtD
Bosutinib—Feeling abnormal—Paclitaxel—breast cancer	1.84e-05	0.00025	CcSEcCtD
Bosutinib—Skin disorder—Docetaxel—breast cancer	1.83e-05	0.000249	CcSEcCtD
Bosutinib—Oedema—Capecitabine—breast cancer	1.83e-05	0.000249	CcSEcCtD
Bosutinib—Gastrointestinal pain—Paclitaxel—breast cancer	1.82e-05	0.000248	CcSEcCtD
Bosutinib—Diarrhoea—Gemcitabine—breast cancer	1.82e-05	0.000247	CcSEcCtD
Bosutinib—Renal failure—Doxorubicin—breast cancer	1.82e-05	0.000247	CcSEcCtD
Bosutinib—Infection—Capecitabine—breast cancer	1.82e-05	0.000247	CcSEcCtD
Bosutinib—Erythema multiforme—Methotrexate—breast cancer	1.81e-05	0.000246	CcSEcCtD
Bosutinib—Dizziness—Irinotecan—breast cancer	1.81e-05	0.000246	CcSEcCtD
Bosutinib—ABL1—lymph node—breast cancer	1.8e-05	0.000302	CbGeAlD
Bosutinib—Nervous system disorder—Capecitabine—breast cancer	1.79e-05	0.000244	CcSEcCtD
Bosutinib—Hepatitis—Epirubicin—breast cancer	1.79e-05	0.000244	CcSEcCtD
Bosutinib—Diarrhoea—Fluorouracil—breast cancer	1.79e-05	0.000243	CcSEcCtD
Bosutinib—Thrombocytopenia—Capecitabine—breast cancer	1.79e-05	0.000243	CcSEcCtD
Bosutinib—Tinnitus—Methotrexate—breast cancer	1.79e-05	0.000243	CcSEcCtD
Bosutinib—Cardiac disorder—Methotrexate—breast cancer	1.78e-05	0.000242	CcSEcCtD
Bosutinib—Skin disorder—Capecitabine—breast cancer	1.78e-05	0.000241	CcSEcCtD
Bosutinib—CSK—Epirubicin—Doxorubicin—breast cancer	1.77e-05	0.0103	CbGdCrCtD
Bosutinib—CSK—Daunorubicin—Doxorubicin—breast cancer	1.77e-05	0.0103	CbGdCrCtD
Bosutinib—Urinary tract disorder—Epirubicin—breast cancer	1.77e-05	0.000241	CcSEcCtD
Bosutinib—Urticaria—Paclitaxel—breast cancer	1.77e-05	0.000241	CcSEcCtD
Bosutinib—Oedema peripheral—Epirubicin—breast cancer	1.77e-05	0.00024	CcSEcCtD
Bosutinib—Connective tissue disorder—Epirubicin—breast cancer	1.76e-05	0.000239	CcSEcCtD
Bosutinib—Body temperature increased—Paclitaxel—breast cancer	1.76e-05	0.000239	CcSEcCtD
Bosutinib—Abdominal pain—Paclitaxel—breast cancer	1.76e-05	0.000239	CcSEcCtD
Bosutinib—Urethral disorder—Epirubicin—breast cancer	1.76e-05	0.000239	CcSEcCtD
Bosutinib—CSNK1E—Betamethasone—Fluoxymesterone—breast cancer	1.75e-05	0.0102	CbGdCrCtD
Bosutinib—CSNK1E—Dexamethasone—Fluoxymesterone—breast cancer	1.75e-05	0.0102	CbGdCrCtD
Bosutinib—Hepatobiliary disease—Doxorubicin—breast cancer	1.75e-05	0.000238	CcSEcCtD
Bosutinib—Vomiting—Mitoxantrone—breast cancer	1.74e-05	0.000236	CcSEcCtD
Bosutinib—Vomiting—Irinotecan—breast cancer	1.74e-05	0.000236	CcSEcCtD
Bosutinib—Immune system disorder—Methotrexate—breast cancer	1.73e-05	0.000235	CcSEcCtD
Bosutinib—Dizziness—Fluorouracil—breast cancer	1.73e-05	0.000235	CcSEcCtD
Bosutinib—Mediastinal disorder—Methotrexate—breast cancer	1.73e-05	0.000235	CcSEcCtD
Bosutinib—Agranulocytosis—Doxorubicin—breast cancer	1.72e-05	0.000234	CcSEcCtD
Bosutinib—Rash—Mitoxantrone—breast cancer	1.72e-05	0.000234	CcSEcCtD
Bosutinib—Rash—Irinotecan—breast cancer	1.72e-05	0.000234	CcSEcCtD
Bosutinib—Dermatitis—Mitoxantrone—breast cancer	1.72e-05	0.000234	CcSEcCtD
Bosutinib—Dermatitis—Irinotecan—breast cancer	1.72e-05	0.000234	CcSEcCtD
Bosutinib—Musculoskeletal discomfort—Docetaxel—breast cancer	1.72e-05	0.000234	CcSEcCtD
Bosutinib—Headache—Irinotecan—breast cancer	1.71e-05	0.000233	CcSEcCtD
Bosutinib—Headache—Mitoxantrone—breast cancer	1.71e-05	0.000233	CcSEcCtD
Bosutinib—Erythema multiforme—Epirubicin—breast cancer	1.69e-05	0.00023	CcSEcCtD
Bosutinib—Vomiting—Gemcitabine—breast cancer	1.69e-05	0.00023	CcSEcCtD
Bosutinib—CHEK2—Testosterone Propionate—Fluoxymesterone—breast cancer	1.69e-05	0.00984	CbGdCrCtD
Bosutinib—Dyspnoea—Docetaxel—breast cancer	1.68e-05	0.000229	CcSEcCtD
Bosutinib—Rash—Gemcitabine—breast cancer	1.68e-05	0.000228	CcSEcCtD
Bosutinib—Dermatitis—Gemcitabine—breast cancer	1.68e-05	0.000228	CcSEcCtD
Bosutinib—Tinnitus—Epirubicin—breast cancer	1.67e-05	0.000227	CcSEcCtD
Bosutinib—Malnutrition—Methotrexate—breast cancer	1.67e-05	0.000227	CcSEcCtD
Bosutinib—Headache—Gemcitabine—breast cancer	1.67e-05	0.000227	CcSEcCtD
Bosutinib—Musculoskeletal discomfort—Capecitabine—breast cancer	1.67e-05	0.000226	CcSEcCtD
Bosutinib—Cardiac disorder—Epirubicin—breast cancer	1.66e-05	0.000226	CcSEcCtD
Bosutinib—Vomiting—Fluorouracil—breast cancer	1.66e-05	0.000226	CcSEcCtD
Bosutinib—Hepatitis—Doxorubicin—breast cancer	1.66e-05	0.000225	CcSEcCtD
Bosutinib—Rash—Fluorouracil—breast cancer	1.65e-05	0.000224	CcSEcCtD
Bosutinib—Dermatitis—Fluorouracil—breast cancer	1.65e-05	0.000224	CcSEcCtD
Bosutinib—Decreased appetite—Docetaxel—breast cancer	1.64e-05	0.000223	CcSEcCtD
Bosutinib—Headache—Fluorouracil—breast cancer	1.64e-05	0.000223	CcSEcCtD
Bosutinib—Urinary tract disorder—Doxorubicin—breast cancer	1.64e-05	0.000223	CcSEcCtD
Bosutinib—Oedema peripheral—Doxorubicin—breast cancer	1.63e-05	0.000222	CcSEcCtD
Bosutinib—Dysgeusia—Methotrexate—breast cancer	1.63e-05	0.000222	CcSEcCtD
Bosutinib—Gastrointestinal disorder—Docetaxel—breast cancer	1.63e-05	0.000222	CcSEcCtD
Bosutinib—Connective tissue disorder—Doxorubicin—breast cancer	1.63e-05	0.000222	CcSEcCtD
Bosutinib—Dyspnoea—Capecitabine—breast cancer	1.63e-05	0.000222	CcSEcCtD
Bosutinib—Fatigue—Docetaxel—breast cancer	1.63e-05	0.000221	CcSEcCtD
Bosutinib—Urethral disorder—Doxorubicin—breast cancer	1.63e-05	0.000221	CcSEcCtD
Bosutinib—Nausea—Irinotecan—breast cancer	1.62e-05	0.000221	CcSEcCtD
Bosutinib—Nausea—Mitoxantrone—breast cancer	1.62e-05	0.000221	CcSEcCtD
Bosutinib—Immune system disorder—Epirubicin—breast cancer	1.62e-05	0.00022	CcSEcCtD
Bosutinib—Mediastinal disorder—Epirubicin—breast cancer	1.62e-05	0.00022	CcSEcCtD
Bosutinib—Pain—Docetaxel—breast cancer	1.61e-05	0.000219	CcSEcCtD
Bosutinib—Back pain—Methotrexate—breast cancer	1.61e-05	0.000219	CcSEcCtD
Bosutinib—Asthenia—Paclitaxel—breast cancer	1.6e-05	0.000217	CcSEcCtD
Bosutinib—Decreased appetite—Capecitabine—breast cancer	1.59e-05	0.000216	CcSEcCtD
Bosutinib—Nausea—Gemcitabine—breast cancer	1.58e-05	0.000215	CcSEcCtD
Bosutinib—ABCB1—embryo—breast cancer	1.58e-05	0.000264	CbGeAlD
Bosutinib—Gastrointestinal disorder—Capecitabine—breast cancer	1.58e-05	0.000215	CcSEcCtD
Bosutinib—Fatigue—Capecitabine—breast cancer	1.58e-05	0.000214	CcSEcCtD
Bosutinib—Pruritus—Paclitaxel—breast cancer	1.58e-05	0.000214	CcSEcCtD
Bosutinib—Erythema multiforme—Doxorubicin—breast cancer	1.57e-05	0.000213	CcSEcCtD
Bosutinib—Pain—Capecitabine—breast cancer	1.56e-05	0.000213	CcSEcCtD
Bosutinib—Malnutrition—Epirubicin—breast cancer	1.56e-05	0.000212	CcSEcCtD
Bosutinib—Feeling abnormal—Docetaxel—breast cancer	1.56e-05	0.000212	CcSEcCtD
Bosutinib—Nausea—Fluorouracil—breast cancer	1.55e-05	0.000211	CcSEcCtD
Bosutinib—Ill-defined disorder—Methotrexate—breast cancer	1.55e-05	0.00021	CcSEcCtD
Bosutinib—Tinnitus—Doxorubicin—breast cancer	1.55e-05	0.00021	CcSEcCtD
Bosutinib—Gastrointestinal pain—Docetaxel—breast cancer	1.54e-05	0.00021	CcSEcCtD
Bosutinib—Anaemia—Methotrexate—breast cancer	1.54e-05	0.00021	CcSEcCtD
Bosutinib—Cardiac disorder—Doxorubicin—breast cancer	1.54e-05	0.000209	CcSEcCtD
Bosutinib—Dysgeusia—Epirubicin—breast cancer	1.53e-05	0.000208	CcSEcCtD
Bosutinib—Diarrhoea—Paclitaxel—breast cancer	1.52e-05	0.000207	CcSEcCtD
Bosutinib—Back pain—Epirubicin—breast cancer	1.51e-05	0.000205	CcSEcCtD
Bosutinib—Feeling abnormal—Capecitabine—breast cancer	1.51e-05	0.000205	CcSEcCtD
Bosutinib—Malaise—Methotrexate—breast cancer	1.5e-05	0.000204	CcSEcCtD
Bosutinib—Immune system disorder—Doxorubicin—breast cancer	1.5e-05	0.000204	CcSEcCtD
Bosutinib—Gastrointestinal pain—Capecitabine—breast cancer	1.49e-05	0.000203	CcSEcCtD
Bosutinib—Mediastinal disorder—Doxorubicin—breast cancer	1.49e-05	0.000203	CcSEcCtD
Bosutinib—Abdominal pain—Docetaxel—breast cancer	1.49e-05	0.000203	CcSEcCtD
Bosutinib—Body temperature increased—Docetaxel—breast cancer	1.49e-05	0.000203	CcSEcCtD
Bosutinib—Leukopenia—Methotrexate—breast cancer	1.49e-05	0.000203	CcSEcCtD
Bosutinib—Dizziness—Paclitaxel—breast cancer	1.47e-05	0.0002	CcSEcCtD
Bosutinib—Cough—Methotrexate—breast cancer	1.46e-05	0.000198	CcSEcCtD
Bosutinib—Urticaria—Capecitabine—breast cancer	1.45e-05	0.000197	CcSEcCtD
Bosutinib—Ill-defined disorder—Epirubicin—breast cancer	1.45e-05	0.000197	CcSEcCtD
Bosutinib—Abdominal pain—Capecitabine—breast cancer	1.45e-05	0.000196	CcSEcCtD
Bosutinib—Body temperature increased—Capecitabine—breast cancer	1.45e-05	0.000196	CcSEcCtD
Bosutinib—Malnutrition—Doxorubicin—breast cancer	1.44e-05	0.000196	CcSEcCtD
Bosutinib—Anaemia—Epirubicin—breast cancer	1.44e-05	0.000196	CcSEcCtD
Bosutinib—Chest pain—Methotrexate—breast cancer	1.42e-05	0.000193	CcSEcCtD
Bosutinib—Arthralgia—Methotrexate—breast cancer	1.42e-05	0.000193	CcSEcCtD
Bosutinib—Myalgia—Methotrexate—breast cancer	1.42e-05	0.000193	CcSEcCtD
Bosutinib—Vomiting—Paclitaxel—breast cancer	1.42e-05	0.000193	CcSEcCtD
Bosutinib—Dysgeusia—Doxorubicin—breast cancer	1.41e-05	0.000192	CcSEcCtD
Bosutinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—breast cancer	1.41e-05	0.000192	CcSEcCtD
Bosutinib—Malaise—Epirubicin—breast cancer	1.41e-05	0.000191	CcSEcCtD
Bosutinib—Rash—Paclitaxel—breast cancer	1.4e-05	0.000191	CcSEcCtD
Bosutinib—Dermatitis—Paclitaxel—breast cancer	1.4e-05	0.000191	CcSEcCtD
Bosutinib—CHEK2—Doxorubicin—Epirubicin—breast cancer	1.4e-05	0.00818	CbGdCrCtD
Bosutinib—Discomfort—Methotrexate—breast cancer	1.4e-05	0.000191	CcSEcCtD
Bosutinib—CHEK2—Danazol—Fluoxymesterone—breast cancer	1.4e-05	0.00818	CbGdCrCtD
Bosutinib—Leukopenia—Epirubicin—breast cancer	1.4e-05	0.00019	CcSEcCtD
Bosutinib—Back pain—Doxorubicin—breast cancer	1.4e-05	0.00019	CcSEcCtD
Bosutinib—Headache—Paclitaxel—breast cancer	1.4e-05	0.00019	CcSEcCtD
Bosutinib—Cough—Epirubicin—breast cancer	1.36e-05	0.000185	CcSEcCtD
Bosutinib—Anaphylactic shock—Methotrexate—breast cancer	1.36e-05	0.000185	CcSEcCtD
Bosutinib—Asthenia—Docetaxel—breast cancer	1.35e-05	0.000184	CcSEcCtD
Bosutinib—CYP3A4—female reproductive system—breast cancer	1.35e-05	0.000226	CbGeAlD
Bosutinib—Infection—Methotrexate—breast cancer	1.35e-05	0.000184	CcSEcCtD
Bosutinib—Ill-defined disorder—Doxorubicin—breast cancer	1.34e-05	0.000182	CcSEcCtD
Bosutinib—ABL1—Idarubicin—Epirubicin—breast cancer	1.34e-05	0.00781	CbGdCrCtD
Bosutinib—ABL1—Daunorubicin—Epirubicin—breast cancer	1.34e-05	0.00781	CbGdCrCtD
Bosutinib—ABL1—Doxorubicin—Epirubicin—breast cancer	1.34e-05	0.00781	CbGdCrCtD
Bosutinib—Pruritus—Docetaxel—breast cancer	1.34e-05	0.000182	CcSEcCtD
Bosutinib—Nervous system disorder—Methotrexate—breast cancer	1.33e-05	0.000181	CcSEcCtD
Bosutinib—Anaemia—Doxorubicin—breast cancer	1.33e-05	0.000181	CcSEcCtD
Bosutinib—Thrombocytopenia—Methotrexate—breast cancer	1.33e-05	0.000181	CcSEcCtD
Bosutinib—Arthralgia—Epirubicin—breast cancer	1.33e-05	0.000181	CcSEcCtD
Bosutinib—Chest pain—Epirubicin—breast cancer	1.33e-05	0.000181	CcSEcCtD
Bosutinib—Myalgia—Epirubicin—breast cancer	1.33e-05	0.000181	CcSEcCtD
Bosutinib—Nausea—Paclitaxel—breast cancer	1.32e-05	0.00018	CcSEcCtD
Bosutinib—Skin disorder—Methotrexate—breast cancer	1.32e-05	0.00018	CcSEcCtD
Bosutinib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—breast cancer	1.32e-05	0.000179	CcSEcCtD
Bosutinib—Discomfort—Epirubicin—breast cancer	1.31e-05	0.000178	CcSEcCtD
Bosutinib—Asthenia—Capecitabine—breast cancer	1.31e-05	0.000178	CcSEcCtD
Bosutinib—Malaise—Doxorubicin—breast cancer	1.3e-05	0.000177	CcSEcCtD
Bosutinib—CHEK2—Epirubicin—Doxorubicin—breast cancer	1.3e-05	0.00757	CbGdCrCtD
Bosutinib—Pruritus—Capecitabine—breast cancer	1.29e-05	0.000176	CcSEcCtD
Bosutinib—Leukopenia—Doxorubicin—breast cancer	1.29e-05	0.000176	CcSEcCtD
Bosutinib—Diarrhoea—Docetaxel—breast cancer	1.29e-05	0.000176	CcSEcCtD
Bosutinib—ABCB1—epithelium—breast cancer	1.29e-05	0.000216	CbGeAlD
Bosutinib—Anaphylactic shock—Epirubicin—breast cancer	1.27e-05	0.000173	CcSEcCtD
Bosutinib—Oedema—Epirubicin—breast cancer	1.27e-05	0.000173	CcSEcCtD
Bosutinib—Infection—Epirubicin—breast cancer	1.27e-05	0.000172	CcSEcCtD
Bosutinib—CHEK2—Norethindrone—Fluoxymesterone—breast cancer	1.26e-05	0.00737	CbGdCrCtD
Bosutinib—Cough—Doxorubicin—breast cancer	1.26e-05	0.000171	CcSEcCtD
Bosutinib—Diarrhoea—Capecitabine—breast cancer	1.25e-05	0.00017	CcSEcCtD
Bosutinib—Nervous system disorder—Epirubicin—breast cancer	1.25e-05	0.00017	CcSEcCtD
Bosutinib—Dizziness—Docetaxel—breast cancer	1.25e-05	0.00017	CcSEcCtD
Bosutinib—Thrombocytopenia—Epirubicin—breast cancer	1.25e-05	0.00017	CcSEcCtD
Bosutinib—Musculoskeletal discomfort—Methotrexate—breast cancer	1.24e-05	0.000169	CcSEcCtD
Bosutinib—ABL1—Idarubicin—Doxorubicin—breast cancer	1.24e-05	0.00722	CbGdCrCtD
Bosutinib—ABL1—Epirubicin—Doxorubicin—breast cancer	1.24e-05	0.00722	CbGdCrCtD
Bosutinib—ABL1—Daunorubicin—Doxorubicin—breast cancer	1.24e-05	0.00722	CbGdCrCtD
Bosutinib—Skin disorder—Epirubicin—breast cancer	1.24e-05	0.000168	CcSEcCtD
Bosutinib—Arthralgia—Doxorubicin—breast cancer	1.23e-05	0.000167	CcSEcCtD
Bosutinib—Chest pain—Doxorubicin—breast cancer	1.23e-05	0.000167	CcSEcCtD
Bosutinib—Myalgia—Doxorubicin—breast cancer	1.23e-05	0.000167	CcSEcCtD
Bosutinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—breast cancer	1.22e-05	0.000166	CcSEcCtD
Bosutinib—Discomfort—Doxorubicin—breast cancer	1.21e-05	0.000165	CcSEcCtD
Bosutinib—Dyspnoea—Methotrexate—breast cancer	1.21e-05	0.000165	CcSEcCtD
Bosutinib—Dizziness—Capecitabine—breast cancer	1.21e-05	0.000164	CcSEcCtD
Bosutinib—Vomiting—Docetaxel—breast cancer	1.2e-05	0.000163	CcSEcCtD
Bosutinib—Rash—Docetaxel—breast cancer	1.19e-05	0.000162	CcSEcCtD
Bosutinib—Dermatitis—Docetaxel—breast cancer	1.19e-05	0.000162	CcSEcCtD
Bosutinib—Decreased appetite—Methotrexate—breast cancer	1.18e-05	0.000161	CcSEcCtD
Bosutinib—Headache—Docetaxel—breast cancer	1.18e-05	0.000161	CcSEcCtD
Bosutinib—Oedema—Doxorubicin—breast cancer	1.18e-05	0.00016	CcSEcCtD
Bosutinib—Anaphylactic shock—Doxorubicin—breast cancer	1.18e-05	0.00016	CcSEcCtD
Bosutinib—Gastrointestinal disorder—Methotrexate—breast cancer	1.17e-05	0.00016	CcSEcCtD
Bosutinib—Fatigue—Methotrexate—breast cancer	1.17e-05	0.000159	CcSEcCtD
Bosutinib—Infection—Doxorubicin—breast cancer	1.17e-05	0.000159	CcSEcCtD
Bosutinib—Pain—Methotrexate—breast cancer	1.16e-05	0.000158	CcSEcCtD
Bosutinib—Vomiting—Capecitabine—breast cancer	1.16e-05	0.000158	CcSEcCtD
Bosutinib—Musculoskeletal discomfort—Epirubicin—breast cancer	1.16e-05	0.000158	CcSEcCtD
Bosutinib—ABCB1—endometrium—breast cancer	1.16e-05	0.000194	CbGeAlD
Bosutinib—Nervous system disorder—Doxorubicin—breast cancer	1.16e-05	0.000157	CcSEcCtD
Bosutinib—Thrombocytopenia—Doxorubicin—breast cancer	1.15e-05	0.000157	CcSEcCtD
Bosutinib—Rash—Capecitabine—breast cancer	1.15e-05	0.000157	CcSEcCtD
Bosutinib—Dermatitis—Capecitabine—breast cancer	1.15e-05	0.000157	CcSEcCtD
Bosutinib—Headache—Capecitabine—breast cancer	1.15e-05	0.000156	CcSEcCtD
Bosutinib—CYP3A4—endocrine gland—breast cancer	1.14e-05	0.000192	CbGeAlD
Bosutinib—Skin disorder—Doxorubicin—breast cancer	1.14e-05	0.000156	CcSEcCtD
Bosutinib—Dyspnoea—Epirubicin—breast cancer	1.14e-05	0.000154	CcSEcCtD
Bosutinib—Nausea—Docetaxel—breast cancer	1.12e-05	0.000152	CcSEcCtD
Bosutinib—Feeling abnormal—Methotrexate—breast cancer	1.12e-05	0.000152	CcSEcCtD
Bosutinib—Gastrointestinal pain—Methotrexate—breast cancer	1.11e-05	0.000151	CcSEcCtD
Bosutinib—Decreased appetite—Epirubicin—breast cancer	1.11e-05	0.00015	CcSEcCtD
Bosutinib—Gastrointestinal disorder—Epirubicin—breast cancer	1.1e-05	0.000149	CcSEcCtD
Bosutinib—Fatigue—Epirubicin—breast cancer	1.1e-05	0.000149	CcSEcCtD
Bosutinib—Pain—Epirubicin—breast cancer	1.09e-05	0.000148	CcSEcCtD
Bosutinib—Nausea—Capecitabine—breast cancer	1.09e-05	0.000148	CcSEcCtD
Bosutinib—Urticaria—Methotrexate—breast cancer	1.08e-05	0.000147	CcSEcCtD
Bosutinib—Body temperature increased—Methotrexate—breast cancer	1.08e-05	0.000146	CcSEcCtD
Bosutinib—Abdominal pain—Methotrexate—breast cancer	1.08e-05	0.000146	CcSEcCtD
Bosutinib—Musculoskeletal discomfort—Doxorubicin—breast cancer	1.07e-05	0.000146	CcSEcCtD
Bosutinib—ABCB1—uterus—breast cancer	1.07e-05	0.000178	CbGeAlD
Bosutinib—Dyspnoea—Doxorubicin—breast cancer	1.05e-05	0.000143	CcSEcCtD
Bosutinib—Feeling abnormal—Epirubicin—breast cancer	1.05e-05	0.000143	CcSEcCtD
Bosutinib—ABCB1—pituitary gland—breast cancer	1.05e-05	0.000175	CbGeAlD
Bosutinib—ABCB1—adipose tissue—breast cancer	1.04e-05	0.000174	CbGeAlD
Bosutinib—Gastrointestinal pain—Epirubicin—breast cancer	1.04e-05	0.000142	CcSEcCtD
Bosutinib—Decreased appetite—Doxorubicin—breast cancer	1.02e-05	0.000139	CcSEcCtD
Bosutinib—Gastrointestinal disorder—Doxorubicin—breast cancer	1.02e-05	0.000138	CcSEcCtD
Bosutinib—Fatigue—Doxorubicin—breast cancer	1.02e-05	0.000138	CcSEcCtD
Bosutinib—Urticaria—Epirubicin—breast cancer	1.01e-05	0.000138	CcSEcCtD
Bosutinib—Pain—Doxorubicin—breast cancer	1.01e-05	0.000137	CcSEcCtD
Bosutinib—Body temperature increased—Epirubicin—breast cancer	1.01e-05	0.000137	CcSEcCtD
Bosutinib—Abdominal pain—Epirubicin—breast cancer	1.01e-05	0.000137	CcSEcCtD
Bosutinib—Asthenia—Methotrexate—breast cancer	9.76e-06	0.000133	CcSEcCtD
Bosutinib—Feeling abnormal—Doxorubicin—breast cancer	9.71e-06	0.000132	CcSEcCtD
Bosutinib—Gastrointestinal pain—Doxorubicin—breast cancer	9.64e-06	0.000131	CcSEcCtD
Bosutinib—Pruritus—Methotrexate—breast cancer	9.63e-06	0.000131	CcSEcCtD
Bosutinib—ABCB1—female reproductive system—breast cancer	9.58e-06	0.00016	CbGeAlD
Bosutinib—Urticaria—Doxorubicin—breast cancer	9.36e-06	0.000127	CcSEcCtD
Bosutinib—ABCB1—adrenal gland—breast cancer	9.35e-06	0.000156	CbGeAlD
Bosutinib—Abdominal pain—Doxorubicin—breast cancer	9.32e-06	0.000127	CcSEcCtD
Bosutinib—Body temperature increased—Doxorubicin—breast cancer	9.32e-06	0.000127	CcSEcCtD
Bosutinib—Diarrhoea—Methotrexate—breast cancer	9.31e-06	0.000127	CcSEcCtD
Bosutinib—Asthenia—Epirubicin—breast cancer	9.14e-06	0.000124	CcSEcCtD
Bosutinib—ABCB1—bone marrow—breast cancer	9.04e-06	0.000151	CbGeAlD
Bosutinib—Pruritus—Epirubicin—breast cancer	9.01e-06	0.000122	CcSEcCtD
Bosutinib—Dizziness—Methotrexate—breast cancer	9e-06	0.000122	CcSEcCtD
Bosutinib—ABCB1—female gonad—breast cancer	8.71e-06	0.000146	CbGeAlD
Bosutinib—Diarrhoea—Epirubicin—breast cancer	8.71e-06	0.000118	CcSEcCtD
Bosutinib—Vomiting—Methotrexate—breast cancer	8.65e-06	0.000118	CcSEcCtD
Bosutinib—Rash—Methotrexate—breast cancer	8.58e-06	0.000117	CcSEcCtD
Bosutinib—Dermatitis—Methotrexate—breast cancer	8.57e-06	0.000117	CcSEcCtD
Bosutinib—Headache—Methotrexate—breast cancer	8.53e-06	0.000116	CcSEcCtD
Bosutinib—Asthenia—Doxorubicin—breast cancer	8.45e-06	0.000115	CcSEcCtD
Bosutinib—Dizziness—Epirubicin—breast cancer	8.42e-06	0.000114	CcSEcCtD
Bosutinib—Pruritus—Doxorubicin—breast cancer	8.34e-06	0.000113	CcSEcCtD
Bosutinib—ABCB1—endocrine gland—breast cancer	8.1e-06	0.000136	CbGeAlD
Bosutinib—Vomiting—Epirubicin—breast cancer	8.1e-06	0.00011	CcSEcCtD
Bosutinib—Nausea—Methotrexate—breast cancer	8.08e-06	0.00011	CcSEcCtD
Bosutinib—Diarrhoea—Doxorubicin—breast cancer	8.06e-06	0.00011	CcSEcCtD
Bosutinib—Rash—Epirubicin—breast cancer	8.03e-06	0.000109	CcSEcCtD
Bosutinib—Dermatitis—Epirubicin—breast cancer	8.02e-06	0.000109	CcSEcCtD
Bosutinib—Headache—Epirubicin—breast cancer	7.98e-06	0.000108	CcSEcCtD
Bosutinib—Dizziness—Doxorubicin—breast cancer	7.79e-06	0.000106	CcSEcCtD
Bosutinib—Nausea—Epirubicin—breast cancer	7.56e-06	0.000103	CcSEcCtD
Bosutinib—Vomiting—Doxorubicin—breast cancer	7.49e-06	0.000102	CcSEcCtD
Bosutinib—Rash—Doxorubicin—breast cancer	7.43e-06	0.000101	CcSEcCtD
Bosutinib—Dermatitis—Doxorubicin—breast cancer	7.42e-06	0.000101	CcSEcCtD
Bosutinib—Headache—Doxorubicin—breast cancer	7.38e-06	0.0001	CcSEcCtD
Bosutinib—Nausea—Doxorubicin—breast cancer	7e-06	9.51e-05	CcSEcCtD
Bosutinib—ABCB1—lymph node—breast cancer	5.6e-06	9.38e-05	CbGeAlD
Bosutinib—SRC—Disease—STAT3—breast cancer	8.74e-08	8.41e-07	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—CDKN1B—breast cancer	8.71e-08	8.38e-07	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—MTHFR—breast cancer	8.71e-08	8.37e-07	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—VEGFA—breast cancer	8.7e-08	8.37e-07	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—KRAS—breast cancer	8.68e-08	8.34e-07	CbGpPWpGaD
Bosutinib—FYN—Disease—HRAS—breast cancer	8.66e-08	8.32e-07	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—TP53—breast cancer	8.63e-08	8.3e-07	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—AKT1—breast cancer	8.62e-08	8.29e-07	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—STAT3—breast cancer	8.62e-08	8.29e-07	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—AKT1—breast cancer	8.62e-08	8.29e-07	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—SRC—breast cancer	8.61e-08	8.28e-07	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—HRAS—breast cancer	8.61e-08	8.28e-07	CbGpPWpGaD
Bosutinib—SRC—Immune System—EGFR—breast cancer	8.61e-08	8.27e-07	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—CXCL8—breast cancer	8.6e-08	8.27e-07	CbGpPWpGaD
Bosutinib—PDGFRB—Disease—IL6—breast cancer	8.6e-08	8.26e-07	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—NCOA2—breast cancer	8.6e-08	8.26e-07	CbGpPWpGaD
Bosutinib—PDGFRB—Immune System—AKT1—breast cancer	8.59e-08	8.26e-07	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—NOS3—breast cancer	8.58e-08	8.25e-07	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—SRC—breast cancer	8.57e-08	8.24e-07	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—CASP3—breast cancer	8.54e-08	8.21e-07	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—IL2—breast cancer	8.53e-08	8.2e-07	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—VEGFA—breast cancer	8.52e-08	8.19e-07	CbGpPWpGaD
Bosutinib—EGFR—Signaling by GPCR—IL6—breast cancer	8.49e-08	8.16e-07	CbGpPWpGaD
Bosutinib—LCK—Disease—KRAS—breast cancer	8.48e-08	8.15e-07	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—PIK3CA—breast cancer	8.47e-08	8.14e-07	CbGpPWpGaD
Bosutinib—LCK—Immune System—PIK3CA—breast cancer	8.44e-08	8.11e-07	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—STAT3—breast cancer	8.44e-08	8.11e-07	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—MAPK3—breast cancer	8.44e-08	8.11e-07	CbGpPWpGaD
Bosutinib—LYN—Immune System—AKT1—breast cancer	8.41e-08	8.09e-07	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—CDKN1B—breast cancer	8.4e-08	8.07e-07	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—VEGFA—breast cancer	8.39e-08	8.07e-07	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—HRAS—breast cancer	8.37e-08	8.05e-07	CbGpPWpGaD
Bosutinib—ABL1—Immune System—AKT1—breast cancer	8.37e-08	8.05e-07	CbGpPWpGaD
Bosutinib—SRC—Disease—MAPK3—breast cancer	8.35e-08	8.03e-07	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—VEGFA—breast cancer	8.34e-08	8.02e-07	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—FASN—breast cancer	8.34e-08	8.01e-07	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—CCND1—breast cancer	8.31e-08	7.99e-07	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—AKT1—breast cancer	8.31e-08	7.99e-07	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—STAT3—breast cancer	8.31e-08	7.99e-07	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—BCHE—breast cancer	8.3e-08	7.98e-07	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—JUN—breast cancer	8.3e-08	7.98e-07	CbGpPWpGaD
Bosutinib—FYN—Disease—IL6—breast cancer	8.29e-08	7.97e-07	CbGpPWpGaD
Bosutinib—FYN—Immune System—AKT1—breast cancer	8.28e-08	7.96e-07	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—STAT3—breast cancer	8.26e-08	7.94e-07	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—HRAS—breast cancer	8.26e-08	7.94e-07	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—IL6—breast cancer	8.24e-08	7.92e-07	CbGpPWpGaD
Bosutinib—MAP2K1—Immune System—AKT1—breast cancer	8.23e-08	7.92e-07	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—MAPK3—breast cancer	8.23e-08	7.92e-07	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—CTNNB1—breast cancer	8.23e-08	7.92e-07	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—CASP3—breast cancer	8.23e-08	7.91e-07	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—IL2—breast cancer	8.22e-08	7.9e-07	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—MYC—breast cancer	8.21e-08	7.89e-07	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—SLC5A5—breast cancer	8.2e-08	7.88e-07	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—TP53—breast cancer	8.19e-08	7.87e-07	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—TGFB1—breast cancer	8.19e-08	7.87e-07	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—MDM2—breast cancer	8.14e-08	7.83e-07	CbGpPWpGaD
Bosutinib—SRC—Immune System—KRAS—breast cancer	8.13e-08	7.82e-07	CbGpPWpGaD
Bosutinib—MAP2K2—Disease—AKT1—breast cancer	8.13e-08	7.81e-07	CbGpPWpGaD
Bosutinib—SRC—Disease—MYC—breast cancer	8.12e-08	7.81e-07	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—RAF1—breast cancer	8.11e-08	7.8e-07	CbGpPWpGaD
Bosutinib—SRC—Disease—TGFB1—breast cancer	8.1e-08	7.79e-07	CbGpPWpGaD
Bosutinib—EGFR—Immune System—HRAS—breast cancer	8.1e-08	7.79e-07	CbGpPWpGaD
Bosutinib—EGFR—Disease—PIK3CA—breast cancer	8.08e-08	7.77e-07	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—RELA—breast cancer	8.08e-08	7.77e-07	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—MMP9—breast cancer	8.07e-08	7.76e-07	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—MAPK3—breast cancer	8.06e-08	7.75e-07	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—CDKN1A—breast cancer	8.04e-08	7.73e-07	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—CAV1—breast cancer	8.03e-08	7.72e-07	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—ERBB2—breast cancer	8.03e-08	7.72e-07	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—EGFR—breast cancer	8.03e-08	7.72e-07	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—PTEN—breast cancer	8.02e-08	7.71e-07	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—IL6—breast cancer	8.01e-08	7.71e-07	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—CCND1—breast cancer	8.01e-08	7.7e-07	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—MYC—breast cancer	8.01e-08	7.7e-07	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—JUN—breast cancer	7.99e-08	7.69e-07	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—TGFB1—breast cancer	7.99e-08	7.68e-07	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—PIK3CA—breast cancer	7.97e-08	7.66e-07	CbGpPWpGaD
Bosutinib—SRC—Disease—EGFR—breast cancer	7.95e-08	7.64e-07	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—MAPK3—breast cancer	7.94e-08	7.63e-07	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—CTNNB1—breast cancer	7.93e-08	7.63e-07	CbGpPWpGaD
Bosutinib—PDGFRB—Disease—AKT1—breast cancer	7.93e-08	7.62e-07	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—PIK3CB—breast cancer	7.92e-08	7.62e-07	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—MTOR—breast cancer	7.92e-08	7.62e-07	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—SLC2A1—breast cancer	7.92e-08	7.61e-07	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—NQO1—breast cancer	7.92e-08	7.61e-07	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—IL6—breast cancer	7.9e-08	7.6e-07	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—MAPK3—breast cancer	7.89e-08	7.59e-07	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—MAPK8—breast cancer	7.85e-08	7.55e-07	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—MYC—breast cancer	7.84e-08	7.54e-07	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—HRAS—breast cancer	7.83e-08	7.53e-07	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—EGFR—breast cancer	7.83e-08	7.53e-07	CbGpPWpGaD
Bosutinib—EGFR—Signaling by GPCR—AKT1—breast cancer	7.83e-08	7.53e-07	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—TGFB1—breast cancer	7.82e-08	7.52e-07	CbGpPWpGaD
Bosutinib—LCK—Immune System—HRAS—breast cancer	7.81e-08	7.51e-07	CbGpPWpGaD
Bosutinib—LCK—Disease—PIK3CA—breast cancer	7.79e-08	7.49e-07	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—MMP9—breast cancer	7.78e-08	7.48e-07	CbGpPWpGaD
Bosutinib—EGFR—Immune System—IL6—breast cancer	7.75e-08	7.45e-07	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—CDKN1A—breast cancer	7.75e-08	7.45e-07	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—PTEN—breast cancer	7.73e-08	7.43e-07	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—MYC—breast cancer	7.72e-08	7.42e-07	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—TP53—breast cancer	7.71e-08	7.41e-07	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—TGFB1—breast cancer	7.7e-08	7.4e-07	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—MYC—breast cancer	7.68e-08	7.38e-07	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—EGFR—breast cancer	7.67e-08	7.37e-07	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—TGFB1—breast cancer	7.66e-08	7.36e-07	CbGpPWpGaD
Bosutinib—FYN—Disease—AKT1—breast cancer	7.64e-08	7.35e-07	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—CXCL8—breast cancer	7.61e-08	7.32e-07	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—AKT1—breast cancer	7.6e-08	7.31e-07	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—CYP1B1—breast cancer	7.59e-08	7.3e-07	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—KRAS—breast cancer	7.58e-08	7.29e-07	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—MAPK8—breast cancer	7.56e-08	7.27e-07	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—EGFR—breast cancer	7.55e-08	7.26e-07	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—EGFR—breast cancer	7.51e-08	7.22e-07	CbGpPWpGaD
Bosutinib—SRC—Disease—KRAS—breast cancer	7.51e-08	7.22e-07	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—IL6—breast cancer	7.5e-08	7.21e-07	CbGpPWpGaD
Bosutinib—EGFR—Disease—HRAS—breast cancer	7.48e-08	7.19e-07	CbGpPWpGaD
Bosutinib—LCK—Immune System—IL6—breast cancer	7.47e-08	7.18e-07	CbGpPWpGaD
Bosutinib—SRC—Immune System—PIK3CA—breast cancer	7.47e-08	7.18e-07	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—HSP90AA1—breast cancer	7.45e-08	7.16e-07	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—SRC—breast cancer	7.44e-08	7.15e-07	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—CDKN1B—breast cancer	7.43e-08	7.15e-07	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—KRAS—breast cancer	7.4e-08	7.11e-07	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—AKT1—breast cancer	7.39e-08	7.11e-07	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—HRAS—breast cancer	7.37e-08	7.09e-07	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—PIK3CG—breast cancer	7.32e-08	7.03e-07	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—AKT1—breast cancer	7.29e-08	7.01e-07	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—CASP3—breast cancer	7.29e-08	7.01e-07	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—IL2—breast cancer	7.28e-08	7e-07	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—VEGFA—breast cancer	7.25e-08	6.97e-07	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—KRAS—breast cancer	7.24e-08	6.96e-07	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—NCOA1—breast cancer	7.24e-08	6.96e-07	CbGpPWpGaD
Bosutinib—LCK—Disease—HRAS—breast cancer	7.21e-08	6.93e-07	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—STAT3—breast cancer	7.18e-08	6.9e-07	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—SRC—breast cancer	7.17e-08	6.89e-07	CbGpPWpGaD
Bosutinib—EGFR—Disease—IL6—breast cancer	7.16e-08	6.88e-07	CbGpPWpGaD
Bosutinib—EGFR—Immune System—AKT1—breast cancer	7.15e-08	6.88e-07	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—STK11—breast cancer	7.14e-08	6.86e-07	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—CYP19A1—breast cancer	7.14e-08	6.86e-07	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—KRAS—breast cancer	7.13e-08	6.86e-07	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—KRAS—breast cancer	7.09e-08	6.82e-07	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—CCND1—breast cancer	7.09e-08	6.82e-07	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—JUN—breast cancer	7.08e-08	6.8e-07	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—IL6—breast cancer	7.06e-08	6.79e-07	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—CTNNB1—breast cancer	7.02e-08	6.75e-07	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—VEGFA—breast cancer	6.98e-08	6.72e-07	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—PIK3CA—breast cancer	6.97e-08	6.7e-07	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—AKT1—breast cancer	6.92e-08	6.65e-07	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—STAT3—breast cancer	6.92e-08	6.65e-07	CbGpPWpGaD
Bosutinib—SRC—Immune System—HRAS—breast cancer	6.91e-08	6.64e-07	CbGpPWpGaD
Bosutinib—LCK—Disease—IL6—breast cancer	6.9e-08	6.63e-07	CbGpPWpGaD
Bosutinib—SRC—Disease—PIK3CA—breast cancer	6.9e-08	6.63e-07	CbGpPWpGaD
Bosutinib—LCK—Immune System—AKT1—breast cancer	6.89e-08	6.63e-07	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—MMP9—breast cancer	6.89e-08	6.62e-07	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—CDKN1A—breast cancer	6.86e-08	6.6e-07	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—MAPK3—breast cancer	6.86e-08	6.59e-07	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—PTEN—breast cancer	6.85e-08	6.58e-07	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—PIK3CA—breast cancer	6.8e-08	6.54e-07	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—TP53—breast cancer	6.74e-08	6.48e-07	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—MAPK8—breast cancer	6.7e-08	6.44e-07	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—MYC—breast cancer	6.67e-08	6.41e-07	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—PIK3CA—breast cancer	6.66e-08	6.4e-07	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—TGFB1—breast cancer	6.65e-08	6.4e-07	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—COMT—breast cancer	6.64e-08	6.38e-07	CbGpPWpGaD
Bosutinib—SRC—Immune System—IL6—breast cancer	6.61e-08	6.36e-07	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—MAPK3—breast cancer	6.61e-08	6.35e-07	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—GSTP1—breast cancer	6.6e-08	6.35e-07	CbGpPWpGaD
Bosutinib—EGFR—Disease—AKT1—breast cancer	6.6e-08	6.35e-07	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—TP53—breast cancer	6.58e-08	6.32e-07	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—PIK3CA—breast cancer	6.55e-08	6.3e-07	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—PIK3CA—breast cancer	6.52e-08	6.27e-07	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—HMOX1—breast cancer	6.51e-08	6.26e-07	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—AKT1—breast cancer	6.51e-08	6.26e-07	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—ITPR1—breast cancer	6.5e-08	6.25e-07	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—HRAS—breast cancer	6.44e-08	6.2e-07	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—TP53—breast cancer	6.44e-08	6.19e-07	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—PIK3CD—breast cancer	6.43e-08	6.18e-07	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—MYC—breast cancer	6.43e-08	6.18e-07	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—TGFB1—breast cancer	6.41e-08	6.16e-07	CbGpPWpGaD
Bosutinib—SRC—Disease—HRAS—breast cancer	6.38e-08	6.13e-07	CbGpPWpGaD
Bosutinib—LCK—Disease—AKT1—breast cancer	6.36e-08	6.12e-07	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—ALB—breast cancer	6.35e-08	6.1e-07	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—TP53—breast cancer	6.34e-08	6.09e-07	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—TP53—breast cancer	6.3e-08	6.06e-07	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—HRAS—breast cancer	6.29e-08	6.05e-07	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—EGFR—breast cancer	6.29e-08	6.04e-07	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—ABCB1—breast cancer	6.25e-08	6.01e-07	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—VEGFA—breast cancer	6.18e-08	5.94e-07	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—IL6—breast cancer	6.17e-08	5.93e-07	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—KRAS—breast cancer	6.16e-08	5.92e-07	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—HRAS—breast cancer	6.16e-08	5.92e-07	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—TYMS—breast cancer	6.14e-08	5.9e-07	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—STAT3—breast cancer	6.12e-08	5.89e-07	CbGpPWpGaD
Bosutinib—SRC—Disease—IL6—breast cancer	6.11e-08	5.87e-07	CbGpPWpGaD
Bosutinib—SRC—Immune System—AKT1—breast cancer	6.1e-08	5.87e-07	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—NOS3—breast cancer	6.07e-08	5.84e-07	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—PLA2G4A—breast cancer	6.07e-08	5.84e-07	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—GSTM1—breast cancer	6.07e-08	5.84e-07	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—NCOR1—breast cancer	6.07e-08	5.84e-07	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—HRAS—breast cancer	6.06e-08	5.83e-07	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—HRAS—breast cancer	6.03e-08	5.8e-07	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—IL6—breast cancer	6.02e-08	5.79e-07	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—KRAS—breast cancer	5.94e-08	5.71e-07	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—IL6—breast cancer	5.89e-08	5.67e-07	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—MAPK3—breast cancer	5.85e-08	5.62e-07	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—GPX1—breast cancer	5.81e-08	5.59e-07	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—IL6—breast cancer	5.8e-08	5.58e-07	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—IL6—breast cancer	5.77e-08	5.55e-07	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—CYP1A1—breast cancer	5.75e-08	5.53e-07	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—ERCC2—breast cancer	5.71e-08	5.49e-07	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—AKT1—breast cancer	5.69e-08	5.47e-07	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—MYC—breast cancer	5.69e-08	5.47e-07	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—TGFB1—breast cancer	5.68e-08	5.46e-07	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—PIK3CA—breast cancer	5.66e-08	5.44e-07	CbGpPWpGaD
Bosutinib—SRC—Disease—AKT1—breast cancer	5.63e-08	5.42e-07	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—PIK3CB—breast cancer	5.61e-08	5.39e-07	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—EGFR—breast cancer	5.56e-08	5.35e-07	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—PTGS2—breast cancer	5.55e-08	5.34e-07	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—AKT1—breast cancer	5.55e-08	5.34e-07	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—TP53—breast cancer	5.48e-08	5.27e-07	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—PIK3CA—breast cancer	5.46e-08	5.24e-07	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—AKT1—breast cancer	5.44e-08	5.23e-07	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—MTHFR—breast cancer	5.36e-08	5.16e-07	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—AKT1—breast cancer	5.35e-08	5.15e-07	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—AKT1—breast cancer	5.32e-08	5.12e-07	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—TP53—breast cancer	5.28e-08	5.07e-07	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—KRAS—breast cancer	5.26e-08	5.05e-07	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—HRAS—breast cancer	5.24e-08	5.04e-07	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—HRAS—breast cancer	5.05e-08	4.85e-07	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—IL6—breast cancer	5.01e-08	4.82e-07	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—CAV1—breast cancer	4.95e-08	4.76e-07	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—PTEN—breast cancer	4.84e-08	4.66e-07	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—IL6—breast cancer	4.83e-08	4.64e-07	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—PIK3CA—breast cancer	4.83e-08	4.64e-07	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—TP53—breast cancer	4.67e-08	4.49e-07	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—AKT1—breast cancer	4.62e-08	4.45e-07	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—PIK3CG—breast cancer	4.51e-08	4.33e-07	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—HRAS—breast cancer	4.47e-08	4.3e-07	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—AKT1—breast cancer	4.46e-08	4.28e-07	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—IL6—breast cancer	4.28e-08	4.11e-07	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—PIK3CD—breast cancer	3.96e-08	3.81e-07	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—AKT1—breast cancer	3.95e-08	3.79e-07	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—ALB—breast cancer	3.91e-08	3.76e-07	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—NOS3—breast cancer	3.74e-08	3.6e-07	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—PIK3CB—breast cancer	3.45e-08	3.32e-07	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—PTGS2—breast cancer	3.42e-08	3.29e-07	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—PIK3CA—breast cancer	3.42e-08	3.29e-07	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—PTEN—breast cancer	2.98e-08	2.87e-07	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—AKT1—breast cancer	2.79e-08	2.68e-07	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—PIK3CA—breast cancer	2.11e-08	2.02e-07	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—AKT1—breast cancer	1.72e-08	1.65e-07	CbGpPWpGaD
